Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma
about
mTOR inhibitors in advanced renal cell carcinomaThe mTOR signalling pathway in human cancerMetastatic renal cell carcinoma: update on epidemiology, genetics, and therapeutic modalitiesCombination therapy for renal cell cancer: what are possible options?Sunitinib in the treatment of metastatic renal cell carcinomaApproaches to modernize the combination drug development paradigmEvaluating rational non-cross-resistant combination therapy in advanced clear cell renal cell carcinoma: combined mTOR and AKT inhibitor therapy.Pharmacokinetic drug interaction between AEE788 and RAD001 causing thrombocytopenia in patients with glioblastoma.Phase Ib study of tivozanib (AV-951) in combination with temsirolimus in patients with renal cell carcinoma.Phase I trial of sunitinib and temsirolimus in metastatic renal cell carcinoma.Phase I combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapy.A Single-Arm Phase 1b Study of Everolimus and Sunitinib in Patients With Advanced Renal Cell Carcinoma.Treatment Options in Metastatic Renal Cell Carcinoma: Focus on mTOR Inhibitors.Molecular diagnosis and therapy of kidney cancer.Phase I study of the combination of temsirolimus and pazopanib in advanced solid tumorsA phase I dose-escalation study to evaluate safety and tolerability of sorafenib combined with sirolimus in patients with advanced solid cancer.Efficacy and safety of everolimus in korean patients with metastatic renal cell carcinoma following treatment failure with a vascular endothelial growth factor receptor-tyrosine kinase inhibitor.Renal cell carcinoma: molecular biology and targeted therapyStructure, development, preclinical and clinical efficacy of tivozanib (KRN-951, AV-951).Targeted therapies in the management of renal cell carcinoma: role of bevacizumabChallenges and opportunities for converting renal cell carcinoma into a chronic disease with targeted therapies.A phase I clinical-pharmacodynamic study of the farnesyltransferase inhibitor tipifarnib in combination with the proteasome inhibitor bortezomib in advanced acute leukemiasTwo drug interaction studies of sirolimus in combination with sorafenib or sunitinib in patients with advanced malignancies.A phase Ib study of combined VEGFR and mTOR inhibition with vatalanib and everolimus in patients with advanced renal cell carcinomaSurvival with AGS-003, an autologous dendritic cell-based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results.Targeted therapies to treat non-AIDS-defining cancers in patients with HIV on HAART therapy: treatment considerations and research outlook.Experience with sunitinib in the treatment of metastatic renal cell carcinomaA serum metabolomic fingerprint of bevacizumab and temsirolimus combination as first-line treatment of metastatic renal cell carcinomaNCCN Task Force report: optimizing treatment of advanced renal cell carcinoma with molecular targeted therapyA phase I trial of ANG1/2-Tie2 inhibitor trebaninib (AMG386) and temsirolimus in advanced solid tumors (PJC008/NCI♯9041).Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma.Stearoyl-CoA desaturase 1 is a novel molecular therapeutic target for clear cell renal cell carcinoma.Tivozanib in the treatment of renal cell carcinoma.Sunitinib for the management of advanced renal cell carcinoma.Benefits from pharmacological and pharmacokinetic properties of sunitinib for clinical development.Sunitinib for metastatic renal cell carcinoma.Renal cell carcinoma: focus on safety and efficacy of temsirolimus.Present and future therapeutic options for locally advanced and metastatic renal cell carcinoma.Optimizing treatment of metastatic renal cell carcinoma by changing mechanism of action.Sorafenib for the management of advanced renal cell carcinoma.
P2860
Q24612127-8D1B5195-4204-4C5F-9DC7-9D42E163805DQ24627306-2BB7ADB9-6BD8-4549-B4B1-73195AEEDC52Q26852437-0B71C3B9-6C16-4276-B79C-7B7C3F69DCA4Q27011663-97C7B22D-0C0A-4103-87E9-584148EFE6FCQ28072057-630B6AFF-F0A1-4A41-9F2E-5BB4881518F3Q28072074-2D1CECAA-D430-49A2-8B75-8AC3DC8CB1E7Q30663984-4722534A-A218-4FD5-88DC-345D27D543B0Q33397545-10CD1958-051D-4402-A322-F2A12C8FCE1EQ33408127-67884AD1-9AB8-47B7-A861-1041F5B86085Q33419097-9E52054B-2BA6-4C6A-8B1B-CC481D6BB1ADQ33422258-D69964FB-CBB4-4B74-B777-1026D04F8E1FQ33424413-AA537B5C-4B00-4558-B571-8DF6443988E7Q33985467-880AD650-608A-4296-9A3B-6D5B165E9089Q34065685-16144740-96ED-4FC6-B447-B7AC0D65BC17Q34129269-A8AB4E8B-2647-42FD-8B5B-D0FC68E8EDBBQ34363435-001D4394-3978-4921-B3BC-D5639C3F0CC0Q34386054-D743D2C1-934C-4CCF-B645-AD700982D0FBQ34513914-3911FCF5-118E-416F-8572-A5EC03A8227BQ34517849-147C2109-F183-4BA2-ADDE-EA197F3BC161Q34611205-1F8EAAFD-2294-45F0-BE2D-A99492DDE2BBQ34627828-ABA263BD-278B-4719-847F-97C66302C8E3Q34629803-71E40477-1267-4D3A-95EE-4A7286E13361Q34795914-314AAAA1-766D-4C2F-8C86-C7B9B72D2C21Q35135727-EC2F7800-15E4-42B1-8B64-BBB4EF23A678Q35504499-DCB4093D-135E-4BE0-9AEC-0F8E673F7A72Q36040272-52454D39-CE06-4E53-96FD-71EC26AC1DCBQ36231729-8F429AFB-D768-4F59-8B71-96C08A56B6C4Q36287414-2DD58372-E38C-4385-AEFF-3435EF3544ABQ36318627-283ED64E-30A9-4E5A-9BE4-DBB7C3F7C03FQ36480124-8B0A8BAB-C48B-4CD5-86BC-4ECA4EF341F3Q36718942-2C8C21A0-92E5-404D-AA90-A8B63AE99EDCQ36818377-7E2EBA3A-6E98-4A0A-B805-8F24723F2CCEQ36933605-AA309B17-38BA-4FFF-9559-1A408D028A13Q37705402-EA7E0328-D3B2-42D8-83B3-154F0E6CA57CQ37773367-0246AFC5-CDE8-471A-A956-7BFCC583B3E9Q37797460-3CFD354A-CEA6-432F-A8F7-6E33E344C7F5Q37828399-21D705E0-15FB-402D-89F8-BE566184C7F4Q37838448-F266BA79-99C3-47B2-9C5D-7CDC9EB200C5Q37866796-15AC4366-16CF-45A1-BABA-736D536D936CQ37894667-4BB60864-05BB-4051-A1AC-354F7C43F86D
P2860
Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Phase I study combining treatm ...... advanced renal cell carcinoma
@ast
Phase I study combining treatm ...... advanced renal cell carcinoma
@en
type
label
Phase I study combining treatm ...... advanced renal cell carcinoma
@ast
Phase I study combining treatm ...... advanced renal cell carcinoma
@en
prefLabel
Phase I study combining treatm ...... advanced renal cell carcinoma
@ast
Phase I study combining treatm ...... advanced renal cell carcinoma
@en
P2093
P2860
P356
P1476
Phase I study combining treatm ...... advanced renal cell carcinoma
@en
P2093
Peggy L Senico
Premal H Patel
Rafael E Curiel
P2860
P356
10.3816/CGC.2009.N.004
P407
P577
2009-01-01T00:00:00Z